← All trials
NCT04015414
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Jul 15, 2021
- Completion date
- Oct 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ZagrebLead sponsor
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityStudy chair
- University of LjubljanaStudy chair
- University of LjubljanaCollaborator
- University of ZagrebReponsible party - principal investigator
- University of ZagrebCollaborator
- University of ZagrebOverall official - principal investigator
- University of ZagrebStudy chair
- University of ZagrebOfficial
- Harvard UniversityOfficial
- University of LjubljanaOfficial
- University of ZagrebSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.